MicroMass recruits three strategy vets

Share this article:
MicroMass Communications has added three new VP, senior strategists to better address the marketing shift from mass-market communications to a more patient-focused approach.

Account planning veteran Mark Klapper joins the Cary, NC-based relationship marketing agency from Unit 7, where he led planners, analysts and psychologists as EVP, director of planning and consulting services.

Kim Levy, a 17-year pharma marketing veteran of both the corporate and agency sides, joins MicroMass to develop strategy on the agency's oncology accounts. Prior to joining MicroMass, Levy was at Adair-Greene Healthcare Communications.

Rick Mazzetti joins MicroMass with over 20 years of pharma industry experience including marketing, sales management and alliance management positions at GlaxoSmithKline, Quintiles Transnational, and LipoScience. His previous brand management experience lies in the areas of central nervous system, cardiology, women's health, men's health, dermatology, and antibiotics.
President Jay Bigelow said in a statement that these new hires come as the agency addresses the ongoing industry shift away from investing in direct-to-consumer advertising.

“With increased pressure to cut back on direct-to-consumer advertising, we are finding that more and more brands are looking for alternate strategies to communicate with patients and professionals, such as relationship marketing and disease awareness campaigns,” Bigelow said. “Enhanced by these new hires, our strategic services group… [will] help clients navigate through this change.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...